Stock Detail
THE MEDICINES COMPANY
Sector: Biotechnology
Latest Quote @ Sat May 5 21:38:14 (15 min delayed)
| N/A |
N/A |
$32.99 |
-0.33 |
-0.99% |
|
Last Day's Data
| $32.99 |
$33.35 |
$0.00 |
0.00% |
0.00 |
$33.32 |
| $33.10 |
$32.51 |
756,270.00 |
1.82B |
696,403.00 |
56.64 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 33.79 |
33.39 |
32.95 |
32.55 |
32.11 |
Stock Profile
The Medicines Company, a pharmaceutical company, engages in the acquisition, development, and commercialization of acute care hospital products. The company offers Angiomax, a direct thrombin inhibitor, for use as an anticoagulant in patients with unstable angina undergoing coronary angioplasty. It also develops clevelox, an intravenous drug intended for the short-term control of blood pressure in surgical patients, including patients undergoing cardiac surgery; and cangrelor, an antiplatelet agent that prevents platelet aggregation. The company markets, distributes, and sells its products to hospital management, physicians, hospital pharmacists, nurses, and other care staff in the United States, as well as through third-party distributors internationally. It has licensing agreements with Biogen Idec, Inc. and AstraZeneca AB. The company was founded in 1996 and is headquartered in Parsippany, New Jersey.
